Skip to main content
SpringerLink
Log in

Budesonide warrants consideration for treating acute exacerbations of inflammatory bowel disorders

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Scott AJ. Ulcerative colitis and Crohn’s disease. In: Speight T, Sutherland J, editors. New Ethicals Disease Index. 4th ed. Auckland, New Zealand: Adis International, 1995: 223–7

    Google Scholar 

  2. Lennard-Jones JE. Treatment of inflammatory bowel disease — future directions. Res Clin Forum 1995; 17(1): 223–34

    Google Scholar 

  3. Spencer CM, McTavish D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995; 50(5), 854–72

    Article  PubMed  CAS  Google Scholar 

  4. de Kaski MC, Hodgson HJF. Rolling review: inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 567–79

    Article  Google Scholar 

  5. Clissold SP, Heel RC. Budesonide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984; 28: 485–518

    Article  PubMed  CAS  Google Scholar 

  6. British National Formulary No. 30. London: The Pharmaceutical Press, 1995 Sep.

  7. Bianchi Porro G, Prantera C, Campieri M, et al. Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitis. Eur J Gastroenterol Hepatol 1994; 6: 125–30

    Article  Google Scholar 

  8. Löfberg R, Ostergaard Thomsen O, Langholz E, et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994 Dec; 8: 591–5

    Google Scholar 

  9. Löfberg R, Danielsson Å, Nilsson Å, et al. Oral budesonide is comparable to prednisolone in active ulcerative colitis but causes no suppression of plasma cortisol [abstract 1787P]. 10th Congress of Gastroenterology October 207, 1994

  10. Lamers C, Meijer J, Engels, et al. Comparative study of the topically acting glucocorticosteroid budesonide and 5-aminosalicylic acid enema therapy of proctitis and proctosigmoiditis [abstract]. Gastroenterology 1991: 100(5): A223

    Google Scholar 

  11. Lemann M, Rutgeerts P, van Heuvertzwijn R, et al. Comparison of budesonide enema and 5-ASA enema in the treatment of active distal ulcerative colitis [abstract]. 1st United European Gastroenterology Week, Athens, Sep 25–27, 1991

  12. Caesar I, Gross V, Roth M, et al. Treatment of active Crohn’s ileocolitis with oral pH-modified budesonide. Z Gastroenterol 1995; 33: 247–50

    PubMed  CAS  Google Scholar 

  13. Löfberg R, Danielsson Å, Saide L. Oral budesonide in active Crohn’s disease. Aliment Pharmacol Ther 1993 Dec; 7: 611–616

    Article  PubMed  Google Scholar 

  14. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Gastroenterology 1996; 110(1): 45–51

    Article  PubMed  CAS  Google Scholar 

  15. Löfberg R, Rutgeerts P, Malchow H. Budesonide CIR for maintenance of remission in ileocecal Crohn’s disease. A European multicenter placebo controlled trial for 12 months [abstract no. 90]. 10th World Congress of Gastroenterology 1994: 13

  16. Tarpila S, Turunen U, Seppälä K, et al. Budesonide enema in active haemorrhagic proctitis — a controlled trial against hydrocortisone foam enema. Aliment Pharmacol Ther 1994 Dec; 8: 591–5

    Article  PubMed  CAS  Google Scholar 

  17. Rutgeerts P, Löfberg R, Malchow H. et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994 Sep 29; 331: 842–845

    Article  PubMed  CAS  Google Scholar 

  18. Campieri M, Ferguson A, Doe W, et al. Oral budesonide competes favourably with prednisolone in active Crohn’s disease [abstract]. Gastroenterology 1995; 108(4) Suppl.: A790

    Google Scholar 

  19. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide vs 6-methylprednisolone in active Crohn’s disease [abstract]. Gastroenterology 1995; 108(4) Suppl.: A828

    Google Scholar 

  20. Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis. A randomised dose-response trial with prednisolone enema as active control. Scand J Gastroenterol 1991; 26: 1225–30

    Article  Google Scholar 

  21. Greenberg GR, Feagan BG, Martin F. Oral budesonide for active Crohn’s disease. N Engl J Med 1994 Sep 29; 331: 836–41

    Article  PubMed  CAS  Google Scholar 

  22. What place has oral budesonide in Crohn’s disease? Pharm J 1996 Mar 16; 256: 372

  23. D’Haens GR, Rutgeerts PJ. How should corticosteroids be used in inflammatory bowel disease. Clin Immunother 1996 May; 5(5): 334–40

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Budesonide warrants consideration for treating acute exacerbations of inflammatory bowel disorders. Drugs Ther. Perspect 7, 1–6 (1996). https://doi.org/10.2165/00042310-199607090-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199607090-00001

Search

Navigation